Absci combines generative AI with a proprietary wet lab validation platform (SoluPro) for de novo antibody design. Their Integrated Drug Creation platform generates novel therapeutic antibodies computationally and validates them in high-throughput E. coli expression systems, reducing drug discovery timelines from years to months.